Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Adaptive Biotechnologies Yönetim
Yönetim kriter kontrolleri 2/4
Adaptive Biotechnologies' CEO'su Chad Robins, Sep2009 tarihinde atandı, in görev süresi 15.08 yıldır. in toplam yıllık tazminatı $ 8.90M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.4% maaş ve 92.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.23% ine doğrudan sahiptir ve bu hisseler $ 9.29M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.6 yıl ve 8.8 yıldır.
Anahtar bilgiler
Chad Robins
İcra Kurulu Başkanı
US$8.9m
Toplam tazminat
| CEO maaş yüzdesi | 7.4% |
| CEO görev süresi | 15.1yrs |
| CEO sahipliği | 1.2% |
| Yönetim ortalama görev süresi | 5.6yrs |
| Yönetim Kurulu ortalama görev süresi | 8.8yrs |
Son yönetim güncellemeleri
Recent updates
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Our First Assessment On Adaptive Biotechnologies
Dec 16CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
Tazminat ve Piyasa: Chad 'nin toplam tazminatı ($USD 8.90M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.23M ).
Tazminat ve Kazançlar: Chad şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Chad Robins (49 yo)
15.1yrs
Görev süresi
US$8,904,267
Tazminat
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 15.1yrs | US$8.90m | 1.23% $ 9.3m | |
| President & COO | 6.7yrs | US$2.97m | 0.32% $ 2.4m | |
| Co-Founder & Chief Scientific Officer | 15.1yrs | US$8.61m | 0.69% $ 5.2m | |
| Chief Commercial Officer of Immune Medicine | 6.7yrs | US$2.88m | 0.22% $ 1.7m | |
| Founder | no data | Veri yok | Veri yok | |
| VP, CFO & Principal Accounting Officer | 3yrs | US$1.66m | 0.10% $ 794.5k | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Senior VP | 5.6yrs | Veri yok | 0.095% $ 716.3k | |
| Chief People Officer | 5.5yrs | Veri yok | 0.17% $ 1.3m | |
| Chief Commercial Officer of MRD | 4.2yrs | Veri yok | 0.17% $ 1.3m | |
| Senior Vice President of MRD BioPharma | 1.1yrs | Veri yok | Veri yok |
5.6yrs
Ortalama Görev Süresi
49.5yo
Ortalama Yaş
Deneyimli Yönetim: ADPT 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 15.1yrs | US$8.90m | 1.23% $ 9.3m | |
| Lead Independent Director | 10.8yrs | US$355.00k | 0.094% $ 709.2k | |
| Member of Corporate Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.6yrs | US$330.00k | 0.035% $ 267.0k | |
| Independent Director | 11.7yrs | US$325.00k | 0.052% $ 390.4k | |
| Independent Director | 6.7yrs | US$310.00k | 0.037% $ 279.1k | |
| Member of Corporate Advisory Board | no data | Veri yok | Veri yok | |
| Member of Corporate Advisory Board | no data | Veri yok | Veri yok | |
| Member of Corporate Advisory Board | no data | Veri yok | Veri yok | |
| Member of Corporate Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 3.6yrs | US$310.00k | 0.038% $ 288.5k |
8.8yrs
Ortalama Görev Süresi
58.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ADPT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).